Company: WHWK
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001628280-25-015269
Chunk: 239

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1
Chunk 239
---
 Other Comprehensive (Loss) IncomeAccumulated Deficit Total Stockholders' EquitySharesPar ValueBalance at December 31, 202224,435 $2 $361,689 $(115)$(203,198)$158,378 Issuance of common stock upon exercise of stock options42 — 78 — — 78 Share-based compensation expense— — 11,954 — — 11,954 Issuance of shares under the employee stock purchase plan77 — 408 — — 408 Unrealized gain on investments, net of tax— — — 142 — 142 Net loss— — — — (65,765)(65,765)Balance at December 31, 202324,554 $2 $374,129 $27 $(268,963)$105,195 Share-based compensation expense— — 10,839 — — 10,839 Issuance of common stock in conjunction with vesting of restricted stock units33 — — — — — Issuance of shares under the employee stock purchase plan94 — 146 — — 146 Unrealized loss on investments, net of tax— — — (11)— (11)Net loss— — — — (63,691)(63,691)Balance at December 31, 202424,681 $2 $385,114 $16 $(332,654)$52,478 

The accompanying notes are an integral part of these consolidated financial statements.

119

WHITEHAWK THERAPEUTICS, INC.

Consolidated Statements of Cash Flows

(in thousands)

Year Ended December 31,20242023Cash flows from operating activities:Net loss$(63,691)$(65,765)Adjustments to reconcile net loss to net cash used in operating activities:Share-based compensation expense10,839 11,954 Amortization of premiums and discounts on short-term investments, net(1,301)(3,136)Non-cash interest expense— 58 Non-cash lease expense460 461 Depreciation and amortization expense193 169 Changes in operating assets and liabilities:Accounts receivable(415)(3,626)Inventory1,116 (3,265)Prepaid expenses and other current assets